Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
gene therapy
life sciences
spinal muscular atrophy
5
×
zolgensma
5
×
biotech
boston blog main
national blog main
national top stories
new york top stories
novartis
boston top stories
clinical trials
fda
new york blog main
san francisco top stories
biogen
deals
drug pricing
hemophilia
national
san diego blog main
san diego top stories
san francisco blog main
spinraza
vc
achromatopsia
adaptive biotechnologies
adeno-associated virus
alexandria venture investments
alicrocumab
altitude life science ventures
american academy of neu
american academy of neurology
american society of gene and cell therapy
arch venture partners
beta-thalassemia
bicycle therapeutics
bill cassidy
billy dunn
bioinnovation capital
What
therapy
drug
gene
healthcare
long
medicine
public
age
america
approved
atrophy
bigger
biggest
bio
biogen
biotech
come
continues
convoluted
crude
cutting
daily
deal
democrats
despite
dreams
driving
edge
effects
emerging
encoded
evrysdi
fda
friday
gave
good
green
head
headaches
help
Language
unset
Current search:
zolgensma
×
" spinal muscular atrophy "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy